Jardiance Cost in New Jersey 2026: Prices, Insurance, Medicaid, and Compounded Options

What Does Jardiance Cost Out of Pocket in New Jersey?

The manufacturer list price for Jardiance in 2026 is approximately $680 per month, and that same figure reflects the average cash-pay price at New Jersey retail pharmacies. Without insurance or a discount program, a 30-day supply of either the 10 mg or 25 mg tablet costs patients roughly that amount. Prices vary by pharmacy chain and location across the state.

Boehringer Ingelheim and Eli Lilly set Jardiance's wholesale acquisition cost at roughly $680 for a 30-tablet supply [1]. GoodRx and similar aggregators may show slightly lower figures at specific NJ pharmacies, but the range typically falls between $620 and $700 before any discounts. The FDA-approved label confirms Jardiance is available only by prescription in the United States [2].

Patients paying cash should compare prices at CVS, Walgreens, Rite Aid, and independent NJ pharmacies before filling, since negotiated GoodRx rates differ by ZIP code. A 90-day supply, where available, sometimes reduces the per-tablet cost modestly compared with monthly fills.

The EMPA-REG OUTCOME trial, published in the New England Journal of Medicine in 2015 (N=7,020), demonstrated that empagliflozin reduced the risk of cardiovascular death by 38% relative to placebo in patients with type 2 diabetes and established cardiovascular disease (P<0.001) [3]. That cardiovascular mortality benefit, confirmed in subsequent FDA label updates, is part of why clinicians and payers continue to prioritize access to the drug despite its list price [4].

Does New Jersey Medicaid Cover Jardiance?

New Jersey Medicaid covers Jardiance with prior authorization for three FDA-approved indications: type 2 diabetes, heart failure, and chronic kidney disease. Patients who meet clinical criteria and submit the required documentation through their prescriber can access the drug at little or no cost once PA is approved.

The NJ FamilyCare (New Jersey's Medicaid program) preferred drug list requires prescribers to document that the patient has a confirmed diagnosis matching an approved indication and, for the type 2 diabetes indication, that at least one preferred first-line agent such as metformin was tried first or is contraindicated [5]. The American Diabetes Association's 2024 Standards of Care state that SGLT2 inhibitors are recommended for patients with type 2 diabetes and established cardiovascular disease, heart failure, or CKD regardless of baseline HbA1c, which strengthens the clinical rationale for PA approval [6].

Heart failure coverage under NJ Medicaid aligns with the EMPEROR-Reduced trial (N=3,730), in which empagliflozin reduced the composite of cardiovascular death or hospitalization for heart failure by 25% relative to placebo (hazard ratio 0.75 to 95% CI 0.65 to 0.86, P<0.001) [7]. The EMPEROR-Preserved trial (N=5,988) later extended the heart failure indication to patients with preserved ejection fraction [8].

For chronic kidney disease, the EMPA-KIDNEY trial (N=6,609) found that empagliflozin reduced the risk of kidney disease progression or cardiovascular death by 28% compared with placebo (hazard ratio 0.72 to 95% CI 0.64 to 0.82, P<0.001), forming the clinical basis for the CKD indication that NJ Medicaid now covers [9].

Prescribers initiating a PA request in New Jersey should submit chart documentation confirming the diagnosis, relevant lab values (eGFR for CKD, echocardiogram findings for heart failure), and prior medication history. Most managed care organizations within NJ FamilyCare process PA decisions within 72 hours of a complete submission.

Which Insurance Plans Cover Jardiance in New Jersey?

Most commercial insurance plans operating in New Jersey cover Jardiance on their formularies, typically at tier 3 or tier 4, which means patient cost-sharing ranges from $50 to $150 or more per month depending on plan design. Medicare Part D coverage varies by plan, and the Medicare $2,000 out-of-pocket cap enacted by the Inflation Reduction Act may significantly lower annual costs for beneficiaries beginning in 2025 [10].

Horizon Blue Cross Blue Shield of New Jersey, Aetna, Cigna, UnitedHealthcare, and AmeriHealth NJ all include Jardiance on their formularies as of 2026, but tier placement differs. Patients on a plan where Jardiance sits at a high tier should ask their prescriber to submit a formulary exception request supported by cardiovascular or renal outcome data from EMPA-REG OUTCOME [3] or EMPA-KIDNEY [9].

The 2024 Endocrine Society Clinical Practice Guideline on type 2 diabetes management recommends SGLT2 inhibitors for patients with established cardiovascular disease or high cardiovascular risk, providing a clinical justification framework that can accompany formulary exception requests [11].

Medicare Advantage plans in New Jersey must cover drugs on their Part D formulary with at least one SGLT2 inhibitor available. CMS data show that roughly 92% of stand-alone Part D plans nationally covered at least one SGLT2 inhibitor in 2024 [12]. Patients should review their specific plan's 2026 Evidence of Coverage document to confirm tier and step-therapy requirements.

How Does the Boehringer Ingelheim / Lilly Savings Card Work in New Jersey?

The Jardiance savings card, offered jointly by Boehringer Ingelheim and Eli Lilly, allows eligible commercially insured patients in New Jersey to pay as little as $10 per month for a 30-day or 90-day supply. The program covers the gap between what commercial insurance pays and what the patient owes up to a program cap.

Eligibility requires that the patient have commercial (private) insurance that covers Jardiance. Patients enrolled in Medicare, Medicaid, or any other federally funded program are not eligible for the savings card. This exclusion is federally mandated to prevent manufacturer subsidies from artificially reducing government program costs [13].

To activate the card, patients visit the official Jardiance savings program portal, enter their insurance information, and present the card at any participating NJ pharmacy at the point of sale. The discount applies automatically without the pharmacist needing to adjudicate a separate claim. Cards are typically valid for the calendar year and must be renewed annually.

Patients without commercial insurance who do not qualify for NJ Medicaid may apply for the Boehringer Ingelheim Patient Assistance Program, which provides Jardiance at no cost to qualifying low-income individuals. Income thresholds and documentation requirements are listed on the manufacturer's patient assistance portal.

Is Compounded Empagliflozin Legal in New Jersey?

Compounded empagliflozin is available through licensed 503A compounding pharmacies in New Jersey. This means state-licensed pharmacies can legally prepare patient-specific compounded formulations when a prescriber writes a valid prescription, provided the compounded product meets all applicable state and federal requirements.

Section 503A of the Federal Food, Drug, and Cosmetic Act permits traditional compounding pharmacies to prepare compounded drugs for individual patients based on a valid prescription [14]. New Jersey's State Board of Pharmacy licenses 503A compounders and enforces quality and labeling standards consistent with USP guidelines [15]. Empagliflozin is not currently on the FDA's 503B outsourcing facility bulk drug substances list, which means large-scale 503B commercial compounding of empagliflozin for office stock is not permitted federally.

A 503A-compounded empagliflozin prescription in New Jersey is patient-specific: the pharmacy prepares the formulation only after receiving an individualized prescription from a licensed NJ prescriber. The compound may differ in dose, formulation, or excipients from commercial Jardiance tablets. Patients considering this option should discuss bioavailability and quality assurance questions with both their prescriber and the compounding pharmacy before switching.

The cost of compounded empagliflozin at 503A pharmacies in New Jersey has been reported at significantly lower prices than the $680 brand-name list price, with some pharmacies quoting as low as $0 per month under specific patient assistance arrangements, though typical market pricing varies by pharmacy and formulation. Patients should obtain a written quote and a Certificate of Analysis confirming the active pharmaceutical ingredient's purity before proceeding.

The FDA has noted that compounded drugs lack the clinical evidence backing of FDA-approved products and are not proven to be safe or effective in the same manner as approved drugs [16]. Prescribers should weigh this consideration alongside cost when determining whether a compounded formulation is appropriate for a specific patient.

Can You Get Jardiance via Telehealth in New Jersey?

Telehealth prescribing of Jardiance is permitted in New Jersey. A licensed NJ physician or advanced practice provider can evaluate a patient via synchronous audio-video telehealth and, upon determining clinical appropriateness, transmit a Jardiance prescription to a New Jersey pharmacy.

New Jersey's telehealth prescribing law, aligned with the Ryan Haight Online Pharmacy Consumer Protection Act, requires that controlled substances be subject to an in-person evaluation first [17]. Jardiance is not a controlled substance, so this restriction does not apply. A prescriber practicing via telehealth in New Jersey must hold an active NJ license and comply with NJ Board of Medical Examiners telemedicine regulations.

HealthRX prescribers operating in New Jersey can initiate empagliflozin therapy for eligible patients following a comprehensive asynchronous or synchronous evaluation. Laboratory values, including a recent comprehensive metabolic panel and eGFR, should be reviewed before prescribing, since Jardiance is not recommended when eGFR is below 20 mL/min/1.73 m² for the glycemic indication [2].

The American College of Cardiology's 2022 heart failure guideline gives SGLT2 inhibitors a Class I recommendation for patients with HFrEF regardless of diabetes status, stating that "SGLT2 inhibitors are recommended to reduce hospitalizations for HF and cardiovascular mortality" [18]. Telehealth prescribers in NJ working with heart failure patients can cite this guidance when documenting clinical rationale.

What Clinical Evidence Supports Empagliflozin's Cost-Effectiveness?

The clinical evidence base for empagliflozin is among the strongest in the SGLT2 inhibitor class. EMPA-REG OUTCOME (N=7,020, published NEJM 2015) showed a 38% relative reduction in cardiovascular death versus placebo over a median 3.1 years of follow-up in patients with type 2 diabetes and established cardiovascular disease [3]. The number needed to treat to prevent one cardiovascular death over three years was 39.

EMPEROR-Reduced (N=3,730) demonstrated a 25% reduction in the composite of cardiovascular death or heart failure hospitalization compared with placebo (HR 0.75, P<0.001) [7]. The absolute risk reduction of 5.3 percentage points translates to a number needed to treat of approximately 19 over 16 months.

EMPA-KIDNEY (N=6,609, published NEJM 2023) showed a 28% reduction in the composite of kidney disease progression or cardiovascular death (HR 0.72, P<0.001), with the benefit observed across a broad range of eGFR values down to 20 mL/min/1.73 m² [9]. That trial recruited patients regardless of diabetes status, confirming a kidney-protective effect independent of glucose lowering [19].

Cost-effectiveness analyses published in JAMA Internal Medicine estimated that empagliflozin's cost per quality-adjusted life year (QALY) gained in patients with heart failure fell below the conventional $100,000 threshold when cardiovascular hospitalizations avoided were included in the model [20]. At the $680 list price, cost-effectiveness is marginal for lower-risk type 2 diabetes patients without cardiovascular or renal disease, which is one reason payers apply step therapy in that population.

The ADA's 2024 Standards of Care specify that SGLT2 inhibitors with proven cardiovascular benefit are preferred agents when a patient has atherosclerotic cardiovascular disease, heart failure, or CKD, independent of metformin use or HbA1c target [6]. That guideline language directly supports prior authorization approvals for NJ Medicaid and commercial insurers in New Jersey.

Empagliflozin Dosing, Safety, and Contraindications Relevant to NJ Patients

Jardiance is available in 10 mg and 25 mg tablets taken once daily in the morning, with or without food [2]. The starting dose for type 2 diabetes is 10 mg once daily; the dose may be increased to 25 mg once daily for additional glycemic control. For heart failure and CKD, the approved dose is 10 mg once daily regardless of diabetes status.

Prescribers in New Jersey should check eGFR before initiating therapy. For the glycemic indication, Jardiance is not recommended when eGFR is persistently below 30 mL/min/1.73 m² [2]. For heart failure and CKD indications, the drug may be used when eGFR is 20 mL/min/1.73 m² or above based on EMPA-KIDNEY data [9].

The most clinically significant adverse effects include genital mycotic infections (reported in approximately 4% of women and 3% of men in pooled trial data), urinary tract infections, and the risk of diabetic ketoacidosis (DKA) in susceptible patients [2]. Patients should be counseled to hold empagliflozin at least three days before elective surgery or prolonged fasting to reduce DKA risk, per ADA guidance [6].

Volume depletion can occur, particularly in patients taking loop diuretics. Among older NJ patients or those on complex diuretic regimens, the prescriber should assess hydration status and blood pressure before initiating [21]. The FDA label notes that Jardiance is not recommended in patients with type 1 diabetes due to the increased DKA risk in that population [2].

Empagliflozin carries a Fournier's gangrene warning following post-marketing reports. Patients with genital hygiene concerns or immunocompromised status require closer monitoring. A 2019 FDA safety communication identified 12 cases of Fournier's gangrene across the SGLT2 inhibitor class in a five-year post-marketing period [22].

How to Get the Lowest Jardiance Price in New Jersey: A Practical Checklist

Several strategies can reduce or eliminate out-of-pocket costs for Jardiance in New Jersey, depending on insurance status and income.

For commercially insured patients, the Boehringer Ingelheim and Lilly savings card reduces cost-sharing to as low as $10 per month. Patients should activate the card before their first fill and confirm the participating pharmacy in their ZIP code accepts it. Retail pharmacy chains in Bergen County, Essex County, and Mercer County all participate in major savings card programs.

For patients on Medicare Part D, the $2,000 annual out-of-pocket cap effective in 2025 under the Inflation Reduction Act limits total drug spending, which may make Jardiance more affordable for beneficiaries with multiple high-cost drugs [10]. Enrolling in a Part D plan that places Jardiance at tier 3 rather than tier 4 can further reduce monthly cost-sharing.

For uninsured or underinsured NJ residents, the Boehringer Ingelheim Cares Foundation Patient Assistance Program provides free Jardiance to qualifying patients with income at or below 400% of the federal poverty level [23]. Applications require proof of income and a prescriber signature.

For patients exploring compounded empagliflozin, verifying the 503A pharmacy's NJ Board of Pharmacy licensure and requesting a Certificate of Analysis for each batch are non-negotiable steps. The FDA recommends patients confirm compounding pharmacy accreditation through the Pharmacy Compounding Accreditation Board (PCAB) [16].

Telehealth platforms operating in New Jersey, including HealthRX, can prescribe Jardiance and coordinate with the patient's preferred NJ pharmacy, including those offering 503A compounded alternatives where clinically appropriate. Patients with a confirmed eGFR above 20 mL/min/1.73 m² and a qualifying indication can typically complete a full prescribing evaluation within one asynchronous visit followed by lab review.